Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 75.86M P/E - EPS this Y 5.50% Ern Qtrly Grth -
Income -65.35M Forward P/E -1.33 EPS next Y -1.40% 50D Avg Chg -1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -37.00%
Dividend N/A Price/Book 1.37 EPS next 5Y - 52W High Chg -74.00%
Recommedations 1.70 Quick Ratio 9.68 Shares Outstanding 92.23M 52W Low Chg 16.00%
Insider Own 5.35% ROA -39.18% Shares Float 79.80M Beta 1.17
Inst Own 34.65% ROE -67.67% Shares Shorted/Prior 441.45K/446.55K Price 0.82
Gross Margin - Profit Margin - Avg. Volume 230,651 Target Price 9.00
Oper. Margin - Earnings Date May 9 Volume 359,425 Change -0.41%
Aptose Biosciences, Inc. News
08/02/22 Aptose Reports Results for the Second Quarter 2022
07/27/22 Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
07/23/22 Is Aptose Biosciences (TSE:APS) In A Good Position To Invest In Growth?
07/19/22 Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022
06/27/22 Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer
06/02/22 CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
06/02/22 Aptose Presents Highlights from Corporate Update and KOL Event
05/31/22 Aptose Biosciences Announces Results of Annual Meeting of Shareholders
05/25/22 Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd
05/12/22 Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd
05/09/22 Aptose Reports Results for the First Quarter 2022
05/04/22 Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
05/03/22 Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference
05/02/22 Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation
04/25/22 Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022
04/07/22 Aptose Announces Executive Management Changes
03/31/22 Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference
03/22/22 Aptose Reports Results for the Fourth Quarter and Full Year 2021
03/08/22 Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

APTO Chatroom

User Image TomCPA Posted - 2 days ago

$APTO CASH: Aptose expects that cash on hand and available capital provide the Company with sufficient resources to fund planned Company operations including research and development into the first quarter of 2024. CATALYST (DATES): APTO-253 : Discontinue Luxeptinib (CG-806): Estimated Primary Completion Date November 2022 HM43239 : Dec 2022 / Data Readout for Dose Esc/Exp TECHNICAL ANALYSIS: Needs to stay over 0.7118 Over 0.92 B/O

User Image Mdefore Posted - 2 days ago

$APTO any news from today’s conference?

User Image ElijahYates26 Posted - 3 days ago

$APTO started small position

User Image hpulse Posted - 3 days ago

$APTO Hi guys. I’m still holding this and will continue. I know in my heart it only takes one key hit to bring about a different dynamic in share price. Yes, pipe dream or whatever, but enough to keep me aboard, and analyst price targets still remain sky high so maybe they too think that opportunity looms. Anyway, I don’t post often, but still letting everyone know I’m very much still here. One day this ship is going to turn, and this is coming from someone been here over a year for what it’s worth. God bless guys and take care!

User Image TomCPA Posted - 3 days ago

$APTO Holding at 0.83 (1/4)

User Image St0ckt0k101 Posted - 4 days ago

$APTO here comes the dump I mentioned! Back under .80 after hitting .92 just yesterday! Don’t expect anything over $1.55 for a pump this year. NO REAL VOLUME HERE FOR THE PAST SEVERAL MONTHS.

User Image Growth_Stocks Posted - 4 days ago


User Image Cole7 Posted - 6 days ago

$APTO “response rate of about 43 percent, and this genetically- and phenotypically defined population represents a potential path for accelerated approval.” Nice gap 👀

User Image BidaskBot Posted - 6 days ago

AptoseBiosciences $APTO BidaskScore is Increased to Sold https://bidaskclub.com/news/company/2022-08-05/APTO

User Image St0ckt0k101 Posted - 6 days ago

$APTO analysis here is that we should be getting more data readouts in the 2H of 2022! If that is true then this can hit $3.00 again this year! The experts say $5-$6 a share in the next 12 months!

User Image St0ckt0k101 Posted - 1 week ago

$APTO still needs more volume and buyers! This will fall back to .80 next week. Other small cap bios were up way more on seemingly no news! Like +25% in a few days. This is up like 10% in the same timeframe! Maybe by Dec 2022 this hits $3.00 again.

User Image liljdog Posted - 1 week ago

$APTO 👹👹👹👹

User Image tickeron Posted - 1 week ago

How does this make you feel? $APTO RSI Indicator left the oversold zone. View odds of downtrend. https://srnk.us/go/3891336

User Image EarningsInsider Posted - 1 week ago

Oppenheimer Raises Aptose Biosciences FY2025 Earnings Estimates to $0.33 EPS (Previously $0.29). https://www.marketbeat.com/x/1264849 $APTO

User Image macroaxis Posted - 1 week ago

$APTO - Puts open interest is shifting for Aptose Bioscns this week https://www.macroaxis.com/stock-options/APTO/Aptose-Bioscns?utm_source=dlvr.it&utm_medium=stocktwits

User Image stocktargetadvisors Posted - 1 week ago

$APTO latest rating from Cantor Fitzgerald Securities on 2022-08-03, setting target price at: USD 6.00 with a rating of . StockTargetAdvisor's own view is Very Bearish with an average target price of USD 6.00. Details: https://www.stocktargetadvisor.com/stock/USA/NSD/APTO

User Image MarketBeat Posted - 1 week ago

Aptose Biosciences's PT cut by Cantor Fitzgerald to $6.00. https://www.marketbeat.com/r/1801432 $APTO

User Image biff1 Posted - 1 week ago

$APTO Yeah I‘d like to see it, but how can analyst seriously give an updated $13 price target, and another at $12 on a stock that’s been as big a turd as this one has. https://www.stck.pro/news/APTO/32320721 $SPY $QQQ $XBI

User Image biff1 Posted - 1 week ago

$APTO APTO sitting on all that potential, over $8 analyst average price target, and just can’t get off the mat. I will continue to hold it though for either a big payday or a complete bust

User Image STCKPRO Posted - 1 week ago

$APTO NEW ARTICLE : Canaccord Genuity Thinks Aptose Biosciences’ Stock is Going to Recover https://www.stck.pro/news/APTO/32320721

User Image stocktowatch7 Posted - 1 week ago

$CRXT, $APTO here goes on http://www.stocksequity.com/active-stocks/teetering-stocks-clarus-therapeutics-holdings-inc-nasdaqcrxt-3-00-aptose-biosciences-inc-nasdaqapto-1-46/

User Image cctranscripts Posted - 1 week ago

Reading CEO explanations submitted regarding $APTO transcript http://www.conferencecalltranscripts.org/include?location=https://seekingalpha.com/article/4528888-aptose-biosciences-inc-apto-ceo-william-rice-on-q2-2022-results-earnings-call-transcript?utm_source=conferencecalltranscripts

User Image STCKPRO Posted - 1 week ago

$APTO NEW ARTICLE : Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2022 Results - Earnings Call Transcript https://www.stck.pro/news/APTO/32299042

User Image stockilluminati Posted - 1 week ago

$APTO https://www.stockilluminati.com/apto/news.php - Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2022 Results - Earnings Call Transcript

User Image Bionco Posted - 1 week ago

$APTO will run out of money in 9 to 12 months?

User Image Last10K Posted - 1 week ago

$APTO just filed a 10-Q Quarterly Report with 5 financial statements and 40 disclosures. Access them all or just read their earnings: https://last10k.com/sec-filings/apto/0001171843-22-005260.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=apto

User Image cctranscripts Posted - 1 week ago

Aptose Biosciences Just Filed Its Quarterly Report: Three months ende... https://www.conferencecalltranscripts.com/summary/?id=11144506 $APTO

User Image Quantisnow Posted - 1 week ago

$APTO 📜 SEC Form 10-Q filed by Aptose Biosciences Inc. https://quantisnow.com/i/3225037?utm_source=stocktwits 45 seconds delayed.

User Image Newsfilter Posted - 1 week ago

$APTO Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC https://newsfilter.io/a/ea8b3a670ce236051aa67c799015e186

User Image Last10K Posted - 1 week ago

$APTO just filed with the SEC a Earnings Release and a Financial Exhibit https://last10k.com/sec-filings/apto/0001171843-22-005256.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=apto

Analyst Ratings
HC Wainwright & Co. Buy Dec 21, 21
HC Wainwright & Co. Buy Nov 12, 21
Oppenheimer Outperform Mar 24, 21
Maxim Group Buy Feb 20, 20
Piper Sandler Overweight Jan 9, 20
H.C. Wainwright Buy Aug 7, 19
Oppenheimer Outperform Jan 25, 19
B. Riley FBR Buy Nov 16, 18
H.C. Wainwright Buy Dec 13, 17
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
- - - Aug 05 Buy 2.65 57,199 151,577 8,948,275 08/05/21
- - - Aug 05 Sell 2.62 60,000 157,200 8,888,275 08/05/21
Whitehead Warren Director Director Dec 28 Option 2.01 20,000 40,200 60,000 12/28/20
Whitehead Warren Director Director Dec 28 Sell 4.06 20,000 81,200 40,000 12/28/20